The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival ...
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on ...
The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...
CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, ...
Among 102 patients with recurrent or metastatic head and neck squamous cell carcinoma evaluable for response, Dr Swiecicki reports a confirmed overall response rate (ORR) of 42% by a blinded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results